Shrink Technologies, a California, USA-based company, has agreed to be acquired in a stock-for-stock transaction by Shrink Nanotechnologies. The transaction closed on May 29 and, as a result, it has become a wholly-owned subsidiary of the latter, a Delaware corporation. The transaction purchase price was just under $9.0 million and called for Shrink to issue 8,888,888 common shares, 50 series C preferred stock and to add one new person to the Shrink board of directors. The closing price of Shrink's stock on the date of the acquisition was $1.01 per share. Shrink has applied for a new stock market symbol with FINRA and expects to trade under a new symbol in the coming weeks.
Commenting on the acquisition, Shrink chief executive Mark Baum stated: "we are pleased to have concluded the transaction to acquire Shrink Technologies, a company with a very promising portfolio of licensed technologies which we believe will be impactful in a number of fast-growing, multi-billion dollar markets. We also welcome to Shrink, a team of world-class scientists and technology innovators from some of our nation's most prestigious academic institutions."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze